Connect with us


Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug

Credit: Image created by Ada H. V. Repetto-Llamazares, Nordic Nanovector ASA. Reston, VA–A new radioimmunotherapy has proven effective in reversing…



Credit: Image created by Ada H. V. Repetto-Llamazares, Nordic Nanovector ASA.

Reston, VA–A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin’s lymphoma mouse model.

Non-Hodgkin’s lymphoma is the most common blood cancer, with the eleventh highest mortality rate of all malignancies worldwide in 2018, according to the American Cancer Society. The monoclonal antibody rituximab was approved for treatment of non-Hodgkin’s lymphoma more than 20 years ago and is currently the standard of care. However, many patients eventually develop resistance against rituximab, which is often associated with changes in expression of the CD20 antigen.

177Lu-lilotomab-satetraxetan (177Lu-lilotomab)–a next-generation b-particle-emitting radioimmunoconjugate–has been shown to increase CD20 expression in different rituximab-sensitive non-Hodgkin’s lymphoma cell lines and to act synergistically with rituximab in a non-Hodgkin’s lymphoma animal model. As such, researchers hypothesized that 177Lu-lilotomab could be used to reverse rituximab resistance in non-Hodgkin’s lymphoma.

In the study, two non-Hodgkin’s lymphoma cell lines–Raji (parent line) and Raji2R (rituximab-resistant line)–were cultured and incubated with either lilotomab, 177Lu-lilotomab or saline. Xenografted mice were then administered either saline, rituximab monotherapy, 177Lu-lilotomab monotherapy or a combination therapy of 177Lu-lilotomab-satetraxetan and rituximab. Tumor volume and survival time were calculated and analyzed.

Exposure of the cell lines to 177Lu-lilotomab resulted in an increase in rituximab binding, as compared with control cells. With no 177Lu-lilotomab exposure, binding in the rituximab-resistant Raji2R cells was on average 36±5 percent compared to untreated Raji cells. After treatment with 177Lu-lilotomab, the rituximab-binding in Raji2R cells increased to 53±3 percent. In contrast, treatment with unlabeled lilotomab or saline had no effect on rituximab binding. Treatment with 177Lu-lilotomab also increased ADCC induction to 30±3 percent of Raji cells, representing a 50 percent increase.

In the xenografted mice, the combination of rituximab with 177Lu-lilotomab synergistically suppressed RajiR2 tumor growth. The median survival time of mice treated with this combination doubled when compared to survival of mice given 177Lu-lilotomab monotherapy and was five times longer than for mice given rituximab monotherapy.

“This work is potentially very important, as it could be a last way out for patients that have become resistant to rituximab. If those patients receive an injection of 177Lu-lilotomab-satetraxetan, they can be treated again with rituximab and have an improved effect,” said Dr. Jostein Dahle, PhD, chief scientific officer at Nordic Nanovector. “In a phase 1b clinical trial, a 100 percent complete response rate was achieved in the first group of patients treated with 177Lu-lilotomab-satetraxetan followed by rituximab. Achieving a complete response is very important, since it usually correlates with an improved duration of response and overall survival.”

Dahle continued, “Combination treatments are the future for cancer therapy. By exploring strategies with radioimmunotherapy together with other drugs, nuclear medicine may play an important role in lymphoma therapy.”


The authors of “177Lu-Lilotomab Satetraxetan has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin’s Lymphoma” include Marion M. Malenge, Nordic Nanovector ASA, Oslo, Norway, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, and Institute for Clinical Medicine, University of Oslo, Oslo, Norway; Sebastian Patzke, Nordic Nanovector ASA, Oslo, Norway, and Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Anne H. Ree, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, and Department of Oncology, Akershus University Hospital, Norway; Trond Stokke, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Peter Ceuppens and Brian Middleton, Inferstats Consulting Ltd., Cheshire, United Kingdom; and Jostein Dahle and Ada H. V. Repetto-Llamazares, Nordic Nanovector ASA, Oslo, Norway.

This study was made available online in April 2020 ahead of final publication in print in October 2020.

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected]

About the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at



0 Users (0 votes)
Criterion 1
What people say... Leave your rating
Sort by:

Be the first to leave a review.

User Avatar
{{{ review.rating_title }}}
{{{review.rating_comment | nl2br}}}

Show more
{{ pageNumber+1 }}
Leave your rating

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


CNBC8 hours ago

Black Friday shopping in stores craters 52% during pandemic as e-commerce sales surge

Traffic at stores on Black Friday fell by 52.1% compared with last year, according to preliminary data from Sensormatic Solutions,...

Bioengineer9 hours ago

Study finds fungal disease of snakes in 19 states, Puerto Rico

Credit: Photo by L. Brian Stauffer CHAMPAIGN, Ill. -- In a collaborative effort between scientists and personnel on military bases...

ZDNET10 hours ago

Digital transfusion: technology leaders urged to openly question existing business models

Now is the time for technology leaders and professionals to step up, do a lot of hand-holding, and guide their...

Ventureburn11 hours ago

New African entrepreneur fund worth $1-million launches

Established by Adam Molai, an African industrialist, the new fund aims to provide entrepreneurs with the capital to kickstart and...

CNBC12 hours ago

Big Tech earnings showed digital ad revenue came roaring back

Big Tech's third-quarter earnings showed that digital ad revenue came roaring back in recent months....

Bioengineer12 hours ago

2020 Neukom Awards honors complex stories in complex times

Winners peer into imagined worlds with real consequencesCredit: Turnbull photo credit: Anju Manandhar; Chiang photo credit: Alan Berner. HANOVER, N.H....

Entrepreneur13 hours ago

10 Apps to Help New Entrepreneurs, Still at Black Friday Pricing

Score limited-time savings on awesome apps....

Coinpedia14 hours ago

Stellar Price Prediction | Will The Stellar Price Gear Up?

Detailed guide on the Stellar price prediction, Stellar coin price, XLM price prediction and much more only on Coinpedia....

Cointelegraph15 hours ago

Bitcoin analysts explain what’s next in the aftermath of BTC plunging to $16.2K

Analysts and traders discuss both bull and bear cases for Bitcoin after BTC's sudden price crash to $16,200...

Reuters16 hours ago

In fresh blow to Trump, U.S. court rejects Pennsylvania election case

A federal appeals court on Friday rejected an attempt by U.S. President Donald Trump's campaign to block President-elect Joe Biden...


    Select language